A high quality, accessible cell therapy for Parkinson’s Disease produced in a scalable bioreactor system for 3D cell expansion and differentiation
Translational Candidate Human pluripotent stem cell expanded and differentiated dopaminergic precursor cells to treat Parkinson’s Disease at high quantity and high quality Area of Impact This candidate uses a 3D…
Development of Autologous Cell Replacement Therapy for Parkinson’s Disease: Path to Personalized Treatment
Translational Candidate autologous iPSC-derived dopaminergic progenitor cells Area of Impact Parkinson's Disease Mechanism of Action Autologous iPSC-derived dopaminergic progenitor cells represent a promising strategy to replace the nigrostriatal cells which…
Lorenz Studer, Winner of the 2017 Ogawa-Yamanaka Stem Cell Prize
Don't miss our video interview with Dr. Lorenz Studer, esteemed stem cell scientist at Sloan Kettering and winner of the 2017 Gladstone Institutes Ogawa-Yamanaka Stem Cell Prize. Read our blog…
Lorenz Studer, Winner of the 2017 Ogawa-Yamanaka Stem Cell Prize
Don't miss our video interview with Dr. Lorenz Studer, esteemed stem cell scientist at Sloan Kettering and winner of the 2017 Gladstone Institutes Ogawa-Yamanaka Stem Cell Prize. Read our blog…
Parkinson’s: Ask the Stem Cell Expert | Xianmin Zeng, Buck Institute
Dr. Xianmin Zeng, associate professor at the Buck Institute for Research on Aging answers your questions about Parkinson's disease and stem cell research. Zeng has a CIRM research grant to…